We propose to submit a new PPG application to facilitate study of the role of the innate immune system in atherogenesis. Once initiated, atherosclerosis has all the characteristics of a chronic inflammatory disease and each Project Leader of the proposed PPG has contributed importantly to the recognition that immunological mechanisms play a central role in modulating disease progression. In vivo studies and our own data suggest that TLRs, which play critical roles in pathogen recognition, also modify atherosclerosis by mediating inflammatory responses to modified lipoproteins and proatherogenic ligands. We propose to use a combination of in vitro and in vivo approaches to understand the regulation of innate immune responses to relevant "pathogens", and their impact on inflammation and atherosclerosis. There is extensive evidence that PPARg and PPARd ligands inhibit inflammatory processes, including TLR-dependent mechanisms, and we will use a combination of molecular, cellular and genomics approaches to understand how they control programs of inflammatory gene expression in macrophages and other cells in the artery. Specifically, we will test the hypothesis that NCoR/SMRT/SUMOylation-dependent pathway plays an important role in vitro and in vivo in mediating the anti-inflammatory and anti-atherogenic effects of PPARg and that PPARd regulates the inflammatory state by control of the concentrations of free and nuclear receptor-bound fractions of the co-repressors BCL-6 and SMRT. The relevance of these observations for atherogenesis will be tested using a variety of unique gene targeted murine models. TLRs of innate immunity sense pathogens, both exogenous and endogenous and induce proinflammatory, proatherogenic responses in macrophages and other cells. Using a variety of unique genetic models, we will determine the coreceptors that pair with TR2 to promote atherosclerosis, the ligands with which they interact, and the molecular and cellular mechanisms responsible. A third focus on innate immunity will be on innate B-1 cells and the IgM natural antibodies (NAbs) they secrete, which appear to target oxidation-specific epitopes as found on OxLDL and apoptotic cells. Using reconstituted mice in which all plasma IgM are NAbs, we will explore their role in atherosclerosis and homeostasis. We will explore the regulation of B-1 cells by TLRs and by nuclear receptors and determine the molecular pathways by which this occurs. In summary, our studies will lead to an increased understanding of the innate network of immune regulation, which could lead to novel therapeutic options to control inflammation and atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL088093-05
Application #
8251188
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Kirby, Ruth
Project Start
2008-05-15
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2012
Total Cost
$2,585,410
Indirect Cost
$468,768
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
van der Valk, Fleur M; Bekkering, Siroon; Kroon, Jeffrey et al. (2016) Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation 134:611-24
Zhao, Xuan; Hirota, Tsuyoshi; Han, Xuemei et al. (2016) Circadian Amplitude Regulation via FBXW7-Targeted REV-ERBα Degradation. Cell 165:1644-57
Wang, Junjian; Zou, June X; Xue, Xiaoqian et al. (2016) ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med 22:488-96
Verbeek, Rutger; Boekholdt, S Matthijs; Stoekenbroek, Robert M et al. (2016) Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res 57:697-705
Yang, Xiaohong; Lee, Sang-Rok; Choi, Yun-Seok et al. (2016) Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res 57:706-13
Gordts, Philip L S M; Nock, Ryan; Son, Ni-Huiping et al. (2016) ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest 126:2855-66
Wall, Christopher E; Yu, Ruth T; Atkins, Anne R et al. (2016) Nuclear receptors and AMPK: can exercise mimetics cure diabetes? J Mol Endocrinol 57:R49-58
Liu, Weilin; Struik, Dicky; Nies, Vera J M et al. (2016) Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 113:2288-93
Ley, Klaus (2016) 2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in Atherosclerosis. Arterioscler Thromb Vasc Biol 36:429-38
Miller, Yury I; Shyy, John Y-J (2016) Context-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation. Trends Endocrinol Metab :

Showing the most recent 10 out of 113 publications